Cancer disparities and black american representation in clinical trials leading to the approval of oral chemotherapy drugs in the united states between 2009 and 2019

Veronica B. Ajewole, Oyinkansola Akindele, Uzoamaka Abajue, Okwuoma Ndulue, Jazzmin J. Marshall, Yhenew T. Mossi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

PURPOSE Over the past 10 years, oral chemotherapy made up about half (45.6%) of all US Food and Drug Administration (FDA)-approved oncolytic and hematologic medications. Given the disparity in incidence and mortality rate because of certain cancers among Black Americans (BAs) in theUnited States, a review of BA's representation in the clinical trials that lead to the development and FDA approval of oral chemotherapy drugs becomes imperative. The objective of this study was to evaluate the reporting of race and inclusion of BA in clinical trials that led to the approval of oral chemotherapy medications by the FDA from 2009 to 2019 in the United States. Additionally, we evaluated the inclusion of BAs in clinical trials of three cancer types with the highest disparity rates among BAs (lung, breast, and prostate). METHODS A retrospective review of all FDA-approved oral chemotherapy drug from 2009-2019 was obtained using the FDA's Hematology/Oncology Approvals & Safety Notifications website. Reports of racial and demographics inclusion were obtained from the clinical trials registry. RESULTS Primary outcome: 142 clinical trials led to FDA approval of 81 oral chemotherapy agents between 2009 and 2019, among which 74 (52%) reported on at least one race and were included in our analysis. 35,933 participants were enrolled in these 74 clinical trials, among which 25,684 (71.47%), 6,061 (16.87%), 889 (2.47%), and 826 (2.30%) were White, Asian, Black, and Hispanic, respectively. BAs were also underrepresented in the clinical trials of three cancer types with the highest disparity rates among this population. CONCLUSION BAs were under-represented in clinical trials leading to FDA approval of oral chemotherapy drugs. There should be more BAs in cancer clinical trials to increase the generalizability of the results, improve outcomes, and eventually close the health disparity gap among this patient population.

Original languageEnglish (US)
Pages (from-to)E623-E628
JournalJCO oncology practice
Volume17
Issue number5
DOIs
StatePublished - May 1 2021

ASJC Scopus subject areas

  • Oncology
  • Health Policy
  • Oncology(nursing)

Fingerprint

Dive into the research topics of 'Cancer disparities and black american representation in clinical trials leading to the approval of oral chemotherapy drugs in the united states between 2009 and 2019'. Together they form a unique fingerprint.

Cite this